China Medical GatewayLoading your healthcare gateway…

Liver Cancer in China

Overview

Primary liver cancer — hepatocellular carcinoma (HCC) — usually arises in cirrhotic livers damaged by hepatitis B or C. China treats the world’s largest HCC population, and its leading liver centers offer every modality at high volume: resection, ablation, transarterial therapy, transplantation and systemic treatment.

A distinctive strength of Chinese programs is conversion therapy — combining targeted and immunotherapy to shrink advanced tumors until they become operable.

Symptoms & Signs

Right upper abdominal pain or a sensation of fullness

Unintentional weight loss and early satiety

Jaundice or abdominal swelling from fluid accumulation in advanced disease

Fatigue and general deterioration in cirrhotic patients

Often detected by ultrasound and AFP surveillance of cirrhosis before symptoms appear

New decompensation of known cirrhosis — ascites, confusion or bleeding — warranting urgent imaging

Diagnosis

Multiphase contrast CT and MRI with LI-RADS criteria characterizing the lesion

Serum AFP and newer biomarkers such as AFP-L3 and DCP

Liver function assessment (Child-Pugh, ALBI) essential for choosing safe treatment

Biopsy when imaging is inconclusive or non-HCC pathology is suspected

Hepatitis B and C serology guiding antiviral management alongside cancer therapy

FibroScan elastography assessing underlying liver stiffness

Treatment Options

Surgical resection for tumors in well-preserved livers, increasingly laparoscopic or robotic

Thermal ablation (radiofrequency or microwave) for small tumors with curative intent

TACE transarterial chemoembolization for intermediate-stage disease

Liver transplantation for selected patients within transplant criteria

Systemic therapy with targeted and immune checkpoint inhibitors for advanced disease

Conversion therapy downstaging tumors to resectable or transplantable status

Advanced Technologies & Novel Drug

Laparoscopic and robotic hepatectomy with ICG fluorescence guidance

Image-navigated ablation fusing ultrasound and CT for precise needle placement

Drug-eluting-bead TACE delivering chemotherapy directly to the tumor

ALPPS staged hepatectomy expanding resectability in marginal livers

Novel first-line targeted-immunotherapy combinations available at Chinese liver centers

Hospital & Specialist

Return to Home